NCT00697229View on ClinicalTrials.gov

Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules

PHASE2CompletedINTERVENTIONAL

Enrollment

99

Participants

Timeline

Start Date

September 30, 1992

Primary Completion Date

May 31, 1996

Study Completion Date

December 31, 1998

Conditions

Hepatitis B

Interventions

BIOLOGICAL

Engerix™-B

Intramuscular injection, 1 or 3 doses

BIOLOGICAL

HBV-MPL vaccine

Intramuscular injection, 1 or 3 doses

Trial Locations (1)

Unknown

GSK Clinical Trials Call Center, Wilrijk

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00697229 - Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules | Biotech Hunter | Biotech Hunter